As we close out 2025, we want to take a moment to express our sincere appreciation to our customers and partners around the world. This past year was defined by meaningful collaboration, scientific progress, and shared achievements that continue to strengthen our impact across the global pharmaceutical and biotechnology landscape.
Thanks to your trust and partnership, we achieved €960 million in net sales and delivered 11% CER growth compared to the previous year. Beyond the numbers, these results reflect the strategic relationships we’ve built, the challenges we’ve solved together, and the innovative therapies we’ve helped bring closer to patients.
We also initiated and advanced more than 40 new projects in 2025, spanning early development through commercial supply. These new programs underscore our collective commitment to advancing complex modalities, enabling seamless scale-up, and reducing time-to-market for key therapeutic areas.
Quality is the foundation on which we operate and one of the most important expectations you place on us. In 2025, we successfully completed 10 Health Authority audits and 80 customer audits across our network. These outcomes reflect the expertise, operational rigor, and continuous improvement mindset embedded across our global teams.
Your feedback and collaboration play a critical role in helping us strengthen systems, harmonize best practices, and ensure we meet the most stringent global standards. Together, we are building a stronger, more resilient supply chain for the future of healthcare.
This year we were honored to be recognized with two significant industry awards:
Both awards reflect advancements with a single goal: to help our customers accelerate development, simplify manufacturing, and access technologies that drive competitive advantage.
To all our customers and partners: thank you for your trust, collaboration, and commitment to advancing science. We look forward to building on this momentum and shaping the next era of healthcare innovation together, powered by teamwork.
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.